The Berlin site has successfully opened its expanded GMP bioconjugation facility, adding significant capacity to our global manufacturing network.

Enhanced Capabilities:

· Commercial-scale bioconjugate production for intermediates and APIs

· Support for early clinical through commercial phases

· Class D and C cleanroom environments

· Enhanced conjugate vaccine and drug manufacturing

· Activated PEG production

· Polymer-based drug delivery excipient manufacturing

This expansion enables us to offer complete project support from initial bioconjugate process development through commercial GMP supply, strengthening our position in the conjugation chemistry market.

Congratulations to Frank Leenders and the team for holding a brilliant event.